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Abstract: Aging of skin is an intricate biological process consisting of two types. While intrinsic 
or chronological aging is an inevitable process, photoaging involves the premature aging of skin 
occurring due to cumulative exposure to ultraviolet radiation. Chronological and photoaging 
both have clinically differentiable manifestations. Various natural and synthetic retinoids 
have been explored for the treatment of aging and many of them have shown histological and 
clinical improvement, but most of the studies have been carried out in patients presenting with 
photoaged skin. Amongst the retinoids, tretinoin possibly is the most potent and certainly the 
most widely investigated retinoid for photoaging therapy. Although retinoids show promise in 
the treatment of skin aging, irritant reactions such as burning, scaling or dermatitis associated 
with retinoid therapy limit their acceptance by patients. This problem is more prominent with 
tretinoin and tazarotene whereas other retinoids mainly represented by retinaldehyde and 
retinol are considerably less irritating. In order to minimize these side effects, various novel 
drug delivery systems have been developed. In particular, nanoparticles have shown a good 
potential in improving the stability, tolerability and efﬁ  cacy of retinoids like tretinoin and 
retinol. However, more elaborate clinical studies are required to conﬁ  rm their advantage in the 
delivery of topical retinoids.
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Introduction
Skin – the largest organ of the body – protects all the other organs from the external 
environment. The skin is a complex organ with multiple structures and cell types 
and divided into three layers: epidermis, dermis, and the subcutaneous tissue. The 
epidermis is mainly composed of keratinocytes, pigment-producing melanocytes, 
and antigen-presenting Langerhans cells. A basement membrane separates the 
epidermis from the dermis, which primarily contains extracellular proteins produced 
by the ﬁ  broblasts below. The vascular supply to the skin resides in the dermis. The 
subcutaneous tissue consists of fat cells that underline the connective tissue network. 
Type I collagen is the most abundant protein in the skin connective tissue. The 
other extracellular matrix proteins, which are a part of the skin connective tissue, 
are collagens (III, V, and VII), elastin, proteoglycans, ﬁ  bronectin, etc. The newly 
synthesized type I procollagen is secreted into the dermal extracellular space where 
it undergoes enzymatic processing to arrange itself into a triple helix conﬁ  guration 
(Rittié and Fisher 2002). 
Apart from environmental protection against radiation, functions of the skin 
include heat regulation, immune response, biochemical synthesis, sensory detection, 
regulation of absorption/loss of water and electrolytes. The stratum corneum 
formed from nonviable corneocytes plays the major role. Keratin is aligned in the 
intercrossed disulﬁ  dic macroﬁ  bres along with ﬁ  laggrin, the main protein component 
of the keratolytic granule. The cells develop a corniﬁ  ed involucre resulting from 
the intercrossing of involucrin and keratohyalin. Lamellar lipids accumulate in Clinical Interventions in Aging 2006:1(4) 328
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the intercellular spaces, which are strongly hydrophobic. 
The combination of the corniﬁ  ed hydrophilic cells with 
the hydrophobic intercellular material forms a barrier for 
the external hydrophilic and hydrophobic substances.
With age the skin’s natural rejuvenation process slows 
drastically and the skin becomes thinner, drier, and less 
elastic (Ramos-E-Silva et al 2001). 
The aging process
Aging represents a biologic attrition at the cellular level 
resulting in decreased reserve capacity and ability to 
perform normal functions occurs throughout an organisms’ 
life span increasing the likelihood of death. Aging is thus 
the result of a genetic program or a clock that is implanted 
in the genetic make-up of each species. One must also 
remember that cumulative damage to the genes and 
proteins derived thereof, result in compromised function 
and homeostatic failure. This leads the organism towards 
premature aging and death, which in turn shall depend on 
its repair systems.
The somatic cells have telomeres at the terminal portion 
of the eukaryotic chromosomes which consist of many 
hundreds of tandem short sequence repeats (TTAGGG) 
predetermining the number of times the cell can divide 
before it senesces. The enzyme DNA polymerase that 
replicates cellular chromosomes during mitosis cannot 
replicate the ﬁ  nal base pairs of each chromosome, resulting 
in progressive telomere shortening with each cellular 
division. A critically short telomere will compromise 
gene transcription and signal cellular senescence which is 
otherwise better known as “apoptosis” (Yaar and Gilchrest 
2001). Human keratinocytes approach replicative senescence 
after 50–100 population doublings in culture and remain 
permanently arrested in the G1 phase of the cell cycle. 
The telomere is just one of the three molecules which were 
found to be crucial for replicative senescence. In addition, 
keratinocytes have an increased resistance to apoptosis, 
thus giving a time window for DNA and protein damage to 
accumulate (Rheinwald et al 2002).
The skin, being the ultimate protective barrier between 
the internal organs and the environment, is exposed to 
ultraviolet (UV) irradiation and to a lesser extent to other 
DNA damaging agents such as cigarette smoke, automobile 
exhaust, and professional exposure. UV irradiation causes 
formation of pyrimidine dimers and the benzo[a]pyrene 
from cigarette smoke causes formation of guanine base pair 
adducts. All this moves hand-in-hand with damage from 
endogenous agents such as reactive oxygen and nitrogen 
species (ROS/RNS) generated by all aerobic cell species 
as part of their routine metabolic processes (Yaar and 
Gilchrest 2001).
Amino acid racemization and interaction of amino acid 
groups with reducing sugars (Maillard reaction) result in 
an altered or total loss of protein functions which does the 
dermal collagen proteins (Yaar and Gilchrest 2001).
Skin aging
Skin aging is inﬂ  uenced by several factors including genetics, 
environmental exposure (UV radiation, xenobiotics, and 
mechanical stress), hormonal changes and metabolic 
processes (generation of reactive chemical compounds such 
as activated oxygen species, sugars and aldehydes). All factors 
together act on the alterations of skin structure, function, 
and appearance. Yet solar UV radiation unquestionably is 
the single major factor responsible for skin aging (Rittié and 
Fisher 2002). 
Intrinsic/chronological aging
Intrinisic/chronological aging is deﬁ  ned by the clinical, 
histological, and physiological decrements that occur in 
the sun-protected skin, affecting the rate of epidermal 
turnover, clearance of chemical substances from the dermis, 
dermal thickness and cellularity, thermoregulation, rate of 
re-epithelialization after wounding, mechanical protection, 
immune responsiveness, sensory perception, sweat and 
sebum production, capacity for vitamin D synthesis and 
vascular reactivity. Clinically, the intrinsically aged skin is 
atrophic, which may result in prominence of vasculature and 
loss of elasticity. The stratum corneum remains relatively 
unchanged but the epidermis thins with a ﬂ  attening of the 
dermo-epidermal junction expressing an increased fragility of 
the skin. There is considerable decrease in dermal thickness 
and vascularity as well as a reduction in the number and 
biosynthetic capacity of the ﬁ  broblast resulting in delayed 
wound healing. With an increasing age, there is a progressive 
decline in the response of keratinocytes and ﬁ  broblasts 
to growth factors, decreasing the proliferative capacity 
(Gilchrest 1996). A decreased immune responsiveness is 
seen with aging since there is a decrease in the number and 
abnormal morphology seen in the antigen-presenting cells. 
Another important function that decreases with aging is 
the formation of vitamin D3 due to decreased formation of 
7-dehydrocholesterol in the reduced epidermal cells (Yaar 
and Gilchrest 2001).Clinical Interventions in Aging 2006:1(4) 329
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Photoaging
Photoaging is the superimposition of photodamage on 
intrinsically aged skin generally bringing about premature 
aging. This speciﬁ  c damage occurs by chronic (multiple) 
exposure of the skin to UV light. Clinically, the skin 
becomes coarse; epidermis thickens (hyperplasia) initially 
and then thins (atrophy), there is laxity, sallowness with 
wrinkles, irregular hyperpigmentation, lentigines, and 
telangiectasias (Gilchrest 1996). The pores of the skin are 
larger, ﬁ  lled with horny material and have a tendency to 
develop Favre-Racouchot’s syndrome (nodular elastoidosis 
with cysts and comedones). There is also an increase in 
development of benign neoplasms (seborrheic keratosis, 
ﬁ  broma, acrochordon, and ruby spots), “premalignant” 
lesions (actinic keratosis, lentigo maligna), and malignant 
lesions (basal and squamous cell carcinomas and malignant 
melanomas) on chronically exposed skin found in the 
face, hands and neck regions (Torras 1996, Oppel and 
Korting 2004). In severely damaged skin, there is loss of 
epidermal polarity (orderly maturation) and individual 
keratinocytes may show atypia, especially the lower 
epidermal layers. More profound changes occur in the 
dermis, where photodamage is characterized by degeneration 
of collagen and deposition of abnormal elastotic material, 
reﬂ  ected by wrinkles, furrows, and yellow discoloration 
of the skin. The greater the photodamage, the more the 
accumulation of thickened, tangled and degraded elastic 
ﬁ  bers (Gilchrest 1996). The surface roughness is not only 
attributed to the changes in the stratum corneum but also 
to the changes in the glycosoaminoglycan (GAG) content 
of the skin. With increase in age, there is a decrease in 
the GAG content. Contradictorily, Bernstein and Uitto 
(1995) found that there is an increase in the GAG content 
in the photoaged skin. Yet GAG does not deposit in the 
papillary dermis, instead it accumulates on the abnormal 
elastotic material, which makes it unavailable as a source 
of hydration resulting in a dull, leathery appearance of 
the skin (Kang, Fisher, et al 2001). The microcirculation 
is also affected by sun exposure. Blood vessels become 
dilated and twisted (telangiectasia) and ﬁ  nally very sparse, 
while their walls are initially thickened and later thinned 
(Gilchrest 1996). UV irradiation of the skin increases the 
reactive oxygen species and decreases the endogenous 
antioxidant enzymes. The superoxide anion is produced 
by energy transfer from several endogenous UV-absorbing 
chromophores including NADH-/NADPH, tryptophan, 
riboﬂ  avin, or trans-urocanic acid (Rittié and Fisher 2002) in 
the presence of molecular water present within the cell. The 
superoxide anion is then converted to hydrogen peroxide, 
which in the presence of transition metal ions such as iron and 
copper undergoes conversion to a highly reactive hydroxyl 
radical. This increased production of ROS alters gene and 
protein structure and function leading to skin damage. 
Table 1 gives an overview of the various epidermal, 
dermal, and clinical signs with which one can differentiate 
between chronological aging and photoaging. 
Mechanism of collagen 
degradation
Mature collagen in skin undergoes continuous turnover, which 
is required for optimal connective tissue function. The unique 
molecular structure of collagen renders it largely resistant to 
nonspeciﬁ  c proteolytic attack. The matrix metalloproteinases 
(MMPs) are a group of enzymes responsible for degradation 
of collagen. The MMPs are members of a large subfamily of 
proteinases with certain common structural features. The human 
Table 1 Comparison of chronological aging and photoaging
 Identiﬁ  cation characteristics
Ageing types  Epidermis  Dermis  Clinical
Chronological   Thinner than normal with lower cell growth,   Elastin ﬁ  bers appear irregular in their     Skin is smooth, 
aging  minor abnormalities in keratinocyte regularity  arrangement, whereas collagen ﬁ  bers begin  unblemished, but
  Normal stratum corneum  to lower in number and thickness  shows saggy appearance
  There is loss of rete pegs here as well      
Photoaging  Thick skin, with acanthosis followed by   Excessive production of elastin ﬁ  bers in an  Smooth, leathery, 
  atrophy of the cells  improper orientation, collagen ﬁ  bres   reddened appearance 
  High basal keratinocyte irregularity Stratum   appear to thicken and then wear out soon  with initially light wrinkles,
  corneum appears compact  Appearance of grenzzone  which later deepen, 
  There is loss of rete pegs here as well      thus showing loss of
     collagen  ﬁ  bersClinical Interventions in Aging 2006:1(4) 330
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family of MMPs is composed of at least 16 members who can 
be classiﬁ  ed into 4 different subfamilies: 1) collagenases, 
2) gelatinases, 3) stromelysins, and 4) membrane MMPs. The 
ﬁ  rst three can cleave native, undenatured interstitial helical 
collagens found in the skin within the triple-helical domain. 
The cleavage site is speciﬁ  c in type I collagen generating 
three-quarter and one-quarter length fragments. Following 
this initial unequal split by collagenase, the resultant denatured 
collagen called gelatin is further degraded by gelatinases and 
stromelysins (Kang, Fisher, et al 2001).
Biochemical pathways that are 
triggered after UV irradiation 
activating cell surface cytokine 
and growth factor receptors
Human skin cells respond to UV radiation by activation of 
multiple cytokine and growth factor receptors. These include 
epidermal growth factors receptors (EGF-R), tumor necrosis 
factor (TNF)-α receptors, platelet activating factor (PAF) 
receptor, interleukin (IL)-1 receptor, insulin receptor and 
platelet derived growth factor. Amongst these, the EGF-R 
activation has been the most studied. It is a single chain 
180 kDa transmembrane protein. The extracellular domain 
possesses high afﬁ  nity binding for EGF and EGF-like 
ligands (transforming growth factor [TGF]-α, amphiregulin 
and heparin binding-EGF) (Rittié and Fisher 2002). The 
intracellular domain possesses intrinsic tyrosine kinase 
activity. EGF-R also known as ErbB1 undergoes homo- or 
heterodimerization with either ErbB2 or ErbB3 resulting 
in the transphosphorylation of speciﬁ  c tyrosine residues. 
EGF-R tyrosine phosphorylation is a well-characterized 
marker for receptor activation and occurs within 10 minutes 
of UV irradiation. Notably, UV fails to induce EGF-R 
tyrosinase phosphorylation in cells expressing mutant 
EGF-R lacking tyrosine kinase activity. UV irradiation 
of EGF-R, like ligand activation, is dependent on 
EGF-R tyrosine kinase-catalysed trans-phosphorylation. 
Alternatively, it has been proposed that UV-induced 
EGF-R tyrosine phosphorylation results from inactivation 
of protein tyrosine phosphatases (PTPs) that function 
to maintain EGF-R in a dephosphorylated basal state. 
Inhibition by specific tyrosine kinase inhibitors results 
in a very rapid dephosphorylation of EGF-R. Treatment 
of the cells with UV irradiation substantially prolonged 
the life of the EGF-R phosphorylated tyrosinases, thus 
suggesting an inhibitory effect of UV on PTPs. This 
inhibitory activity by UV was sensitive to N-acetyl cysteine, 
a scavenger of reactive oxygen intermediates and could 
be mimicked by treating cells with H2O2. UV-induced 
inactivation of PTP activity is postulated to result from 
oxidation of a critical cysteine residue that is present in 
the catalytic active site of all PTP’s to sulfenic acid. This 
oxidation occurs by the exposure of the cysteine residue 
on the PTP to reactive oxygen species which are generated 
within the cells by UV irradiation (Rittié and Fisher 2002). 
This inactivation of PTPs may result in the activation of 
other cell surface receptors and cytokine receptors which 
in turn leads to activation of small GTP-binding protein 
families such as the Rac, Ras, and Cdc42. These are either 
direct or indirect (via other GTP-binding proteins or ROS) 
upstream regulators of mitogen-activated protein kinases 
(MAPKs). The UV irradiation causes increased ROS 
production and simultaneous increase in ceramide levels 
which may also contribute to the activation of MAPK 
pathways. A major effector of the MAPK pathways is 
the transcription factor activator protein-1 (AP-1). AP-1 
is constitutively composed of c-Fos and JunD proteins or 
the other Jun and Fos family proteins (c-Jun, Junb, FosB, 
Fra1, and Fra2) in the nonirradiated skin. The activation of 
MAPKs indirectly activates the transcription factors for AP-1 
formation ie, transcription of the c-Fos and c-Jun genes. 
UV irradiation induces c-Jun mRNA and protein in human 
skin in vivo within 30 min and 1 hour, respectively, and 
protein levels remain elevated for at least 24 hours post UV 
irradiation. Increased levels of c-Jun compete with JunD 
for forming complexes with c-Fos resulting in c-Jun: c-Fos 
AP-1 complexes (Rittié and Fisher 2002). Transcription of 
several MMP family members is regulated by this AP-1 
complex formed throughout the epidermal and dermal cells. 
MMPs are a large family of zinc-requiring endoprotreases 
with a broad range of speciﬁ  cities that together have the 
capacity to degrade all the extracellular matrix proteins. 
Initially, MMPs are synthesized as zymogens (proenzymes) 
which undergo proteolytic degradation to be active. These 
are inhibited by tissue inhibitors of metalloproteinases 
(TIMPs). Several MMPs are upregulated by AP-1 including 
MMP-1 (interstitial collagenase or collagenase1), which 
intitiates the degradation of types I & III ﬁ  brillar collagens, 
MMP-9 (92 kDa gelatinase or gelatinase B) degrades the 
collagen fragments (gelatin) generated by collagenases and 
MMP-3 (stromelysin 1) further degrades collagen type IV of 
the basement membrane and activates proMMP-1. MMP-1, 
MMP-3, and MMP-9 transcripts are induced within 8 hours Clinical Interventions in Aging 2006:1(4) 331
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following UV irradiation. Thus, together MMPs have the 
capacity to completely degrade mature ﬁ  brillar collagen in 
the skin within 24 hours of UV exposure via the induction 
of transcription factor AP-1. In addition to causing collagen 
breakdown, UV radiation impairs new type I collagen 
synthesis and organization of collagen ﬁ  brils in skin in 
vivo. Down-regulation of type I collagen is mediated by 
down-regulation of the transcription of genes that encode for 
type I procollagen. Type I procollagen mRNA and protein 
expression levels are decreased within 8 hours following 
UV irradiation of the human skin in vivo and become 
essentially absent in the upper dermis within 24 hours after 
UV irradiation, consistent with the sustained induction of 
c-Jun and thus AP-1 activation. 
The TGF-β is a major profibrotic cytokine, which 
regulates multiple cellular functions including differentiation, 
proliferation and induction of synthesis of major extracellular 
matrix (ECM) proteins – collagen and elastin (Massague 
1998). In human skin, TGF-β inhibits growth of epidermal 
keratinocytes and stimulates growth of dermal ﬁ  broblasts 
(Massague 2000). TGF-β inhibits the expression of MMP-1 
and MMP-3 by binding to a certain cell surface receptor 
complex (TGF-β receptor proteins: TβR I/II/III), thus 
preventing the breakdown of collagens. UV irradiation 
has been shown to impair the TGF-β signaling pathway 
by reducing TβRII expression and to a lesser extent the 
inhibitory Smad 7. Moreover, the connective tissue growth 
factor is down-regulated after UV irradiation (Rittié and 
Fisher 2002).
In this article, we critically compare the clinical efﬁ  cacy 
and safety of various retinoids that have been in the treatment 
and protection of skin aging.
Retinoids
The importance of retinol (vitamin A) was discovered 
during World War I and subsequent research showed 
that its deficiency gives rise to xerosis and follicular 
hyperkeratosis. The retinoid drug project was launched 
in 1968 to synthesize compounds similar to vitamin A by 
chemical manipulation of its molecule to improve clinical 
efﬁ  cacy and safety. The use of these substances in therapy 
dates back some 3000 years to ancient Egypt, where liver 
was used to treat endemic night blindness. The modern 
history of retinoids, however, began in 1909 when an 
essential factor in the viability of an embryo in the fatty 
extract of the egg yolk, called vitamin A, was discovered. 
Retinoids ﬁ  nally were introduced into the treatment of 
dermatoses including photoaging more than two decades 
ago (Ramos-E-Silva et al 2001).
The retinoid family comprises vitamin A (retinol) and 
its natural derivatives such as retinaldehyde, retinoic acid, 
and retinyl esters, as well as a large number of synthetic 
derivatives (Antille et al 2004). Retinol is a 20-carbon 
molecule that consists of a cyclohexenyl ring, a side chain with 
four double bonds (all in trans conﬁ  guration), and an alcohol 
end group, hence the name all-trans-retinol. The oxidation 
of the alcohol end group in retinol results in the formation 
of an aldehyde (all-trans retinaldehyde or retinal), which can 
be further oxidized to a carboxylic acid (all-trans retinoic 
acid or tretinoin). Vitamin A cannot be synthesized by the 
body; hence it needs to be supplied to the body. Naturally, 
it is present as retinyl esters and beta-carotene. The retinyl 
esters are converted to retinol before absorption from the 
intestine and back to retinyl esters for storage in the liver. In 
the plasma, retinol is bound to plasma-retinol binding proteins. 
Retinol is be metabolized to four important products: retinyl 
esters, all-trans retinoic acid, 14-hydroxy-4, 14-retro retinol, 
and all-trans 3, 4-didehydroretinol, and its esters. Retinoids 
are required for a vast number of biological processes. In 
particular, they are involved in embryogenesis, reproduction, 
vision, growth, inﬂ  ammation, differentiation, proliferation, 
and apoptosis. Retinal is an essential part of the rhodopsin 
pigment, necessary for vision (Roos et al 1998). Retinoids 
are found in the keratinocytes in two forms: retinol and 
retinyl esters – probably the storage form. This esteriﬁ  cation is 
catalysed by two enzymes, acyl CoA: retinol acyltransferase and 
lecithin: retinol acyltransferase (Törmä and Vahlquist 1990). 
The metabolism of retinyl esters to retinol is catalysed by 
retinyl ester hydrolase (Törmä and Vahlquist 1990). 
Retinoid classiﬁ  cation 
Based on the structural features and reﬂ  ecting the time 
of introduction, retinoids can be classiﬁ  ed into various 
generations. The chemical structures of various retinoids 
are shown in Figure 1. 
Mechanism of action 
of topical retinoids
Retinoids are very well known to inﬂ  uence a variety of 
cellular processes, such as cellular growth and differentiation, 
cell surface alterations, and immune modulation. Many of 
their tissue effects are mediated by their interaction with 
speciﬁ  c cellular and nucleic acid receptors. The cellular 
or cytoplasmic receptors include the Cellular Retinoic Clinical Interventions in Aging 2006:1(4) 332
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Acid Binding Protein (CRABP) types I and II and the 
cellular retinol binding protein (Astrom et al 1991). The 
nucleic acid receptors were discovered in 1987 to reveal 
the mechanism of action by which tretinoin and several of 
its analogues would bring about their biological effects. 
This discovery of the existence of a tretinoin speciﬁ  c gene 
transcription factor lead to the realization that tretinoin is a 
hormone. These nuclear receptors are related to a super 
family of nuclear DNA transcription factors, which include 
steroid, thyroid hormone, and vitamin D receptors. They 
comprise two families, each of which are encoded by three 
genes. The nuclear retinoic acid receptor family called RARs 
was the ﬁ  rst to be described and consists of three forms 
(RAR-α, RAR-β, RAR-γ) that are activated by RAR speciﬁ  c 
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all-trans-retinoic acid (tretinoin). As such the RARs 
have distinct DNA and retinoid-binding domains and 
they function in pairs, either pairs of identical receptors 
called homodimers or pairs of different receptors called 
heterodimers. In the human skin, RARs partner with retinoid 
X receptors (RXRs) to form heterodimers (Giguére et al 
1987; Petkovich et al 1987; Brand et al 1988; Fisher et al 
1994; Xiao et al 1995). The retinoid X receptors or RXRs 
are the second family of nuclear receptors which interact 
with 9-cis retinoic acid. Both RARs and RXRs are present 
in the normal skin providing the necessary machinery for 
the retinoid repair process of the photodamaged skin. The 
RAR-γ subtype accounts for nearly 90% of RARs in the 
human epidermis, whereas the RXR-α subtype accounts 
for nearly 90% of the RXRs. Therefore, for the most part, 
the normal human skin is regulated by paired heterodimers 
composed of RAR-γ and RXR-α. The heterodimer complex 
binds to speciﬁ  c elements in the DNA known as retinoic 
acid response elements (RARE) in the promoter region 
of the genes that are regulated by that speciﬁ  c retinoid 
thus regulating the transcriptional activity of that retinoid-
responsive gene. The heterodimer requires only RAR 
speciﬁ  c retinoid (tretinoin) to bind to RARE and initiate 
transcriptional activity; the presence of a RXR binding 
retinoid (9-cis retinoic acid) does not confer additional 
trans-activation induced by the RAR retinoid. However, 
for the heterodimer to function, the RXR protein must be 
physically present to associate with the RAR protein. This 
is probably the way topical retinoids improve photoaging 
by modifying cellular differentiation programs: 1) initiating 
the increase of epidermal proliferation leading to epidermal 
thickening; 2) compaction of the stratum corneum; and 
3) biosynthesis and deposition of the glycosoaminoglycans 
(Grifﬁ  ths et al 1993). 
New retinoids are selective for different RAR’s such 
as the third generation retinoid Adapalene for RAR-β. The 
newest retinoids are antagonists, which have potent anti-
inﬂ  ammatory activity and look promising as topical treatment 
for psoriasis (Grifﬁ  ths et al 1998).
Tretinoin
Tretinoin happens to be the retinoid that is investigated 
more than any other retinoid implicated in the treatment of 
intrinsic or photoaging. Although tretinoin has been used in 
dermatology since the 1960s, its potential in the treatment 
of aging was realized no earlier than in the 1980s. The 
efﬁ  cacy of tretinoin in the treatment of photoaging was 
ﬁ  rst demonstrated by Kligman and colleagues (1984) using 
an animal model of photoaging. The authors observed 
that treatment of photoaged mouse skin with tretinoin 
for 10 weeks resulted in a signiﬁ  cant repair zone of new 
collagen in the papillary dermis, which also correlated with 
wrinkle effacement. This interesting observation prompted 
researchers to investigate the potential of tretinoin in the 
treatment of photoaging. Much later ex-vivo investigations 
carried out by Fisher and colleagues (1996) helped in 
understanding the molecular basis of this observation. 
Fisher and colleagues (1996) found that pretreatment of 
UV irradiated excised (photoaged) skin with 0.1% tretinoin 
cream results in complete blockade of interstitial collagenase 
and gelatinases synthesis thus preventing collagen 
degradation. Moreover, application of 0.1% tretinoin also 
blocked UV-induced activation of the nuclear transcription 
factors AP-1 and NF-κB.
Following the ex-vivo observations, Kligman and 
colleagues (1986) conducted a vehicle-controlled open 
study to evaluate the clinical efﬁ  cacy of 0.05% tretinoin. 
The study involved application of 0.05% tretinoin on the 
photoaged facial and forearm skin for the duration of 
3–12 months. Interestingly, tretinoin resulted in clinical 
improvement of the photoaged skin. Moreover, histological 
examination showed deposition of reticulin ﬁ  bers and 
new dermal collagen formation (type I and III) accompanied 
by angiogenesis in the papillary dermis. Encouraging 
results obtained from this study stimulated researchers 
to conduct a vast number of clinical trials to confirm 
the clinical efficacy of tretinoin in the treatment of 
photoaging.
Considering the exorbitant number of the reports 
available in the literature, we have divided this part in several 
subsections.
Short-term studies on tretinoin
This section should deal with the short-term studies that 
were carried out immediately after the reports by Kligman 
and colleagues (1986). Table 2 provides an overview of 
those studies. In the two double-blind studies a statistically 
signiﬁ  cant clinical improvement of various parameters was 
observed. Furthermore, the tretinoin treated group had a 
“rosy glow” not seen in the control group. Moreover, it was 
observed that the skin condition continued to improve when 
the follow-up assessment was performed after cessation 
of treatment. Hence, studies involving longer duration of 
tretinoin treatment were designed.Clinical Interventions in Aging 2006:1(4) 334
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Long-term studies on tretinoin
Long-term studies on tretinoin were carried out as short-term 
studies showed that the skin condition continued to improve 
in appearance over time. Additionally, another objective was 
to assess the long-term beneﬁ  t-to-risk ratio of the tretinoin 
formulations. For suitability of understanding we have divided 
long-term studies into 6-months studies and studies involving 
more than 6 months.
Studies involving 6-month tretinoin treatment
Most of the 6-month studies that were carried out used 
tretinoin emollient cream that is speciﬁ  cally designed for the 
treatment of photoaging. Additionally, most of these studies 
compared the efﬁ  cacy of the various strengths of tretinoin to 
arrive at the concentration that is optimum for the treatment 
of photoaging. The various 6-month studies that were carried 
out are reported in Table 3. All the 6-month studies did show 
signiﬁ  cant improvement in the clinical signs of photoaging, 
but again the improvement in skin condition continued even 
after 6 months. 
Studies involving tretinoin treatment 
for more than 6 months
The ability of long-term (more than 6 months) tretinoin 
treatment to maintain improvement in photoaging was ﬁ  rst 
evaluated by Ellis and colleagues (1990) in a 22-month 
study carried out in 16 patients with photoaged skin. All 
the subjects used 0.1% tretinoin for the ﬁ  rst 4 months. 
Thereafter, 3 patients continued this regimen, 8 were 
changed to alternate day treatment for the last 12 months, 
and the remaining used 0.05% tretinoin for 5 months and 
then reduced to alternate day application till the end of 
therapy. It was observed that the improvement of wrinkling 
continued up to the 10th month and was maintained 
thereafter. The stratum corneum and epidermal thickness 
returned to the normal during the course of treatment. In 
another trial, Green and colleagues (1993) studied the 
effect of 0.05% tretinoin emollient cream applied daily 
for 12 months. Tretinoin treatment showed significant 
improvement in the clinical signs of photoaging. However, 
the major degree of changes occurred after 6 months and 
later on they tended to remain stable as observed in the 
earlier study. Extension of the study for 6 more months with 
either weekly or thrice weekly application showed further 
improvement in overall signs of photoaging. 
Thereafter, Bhawan and colleagues (1995) evaluated 
the changes occurring at the dermal level in Caucasian skin 
after daily application of 0.05% tretinoin cream for a period 
of 12 months. Interestingly, no signiﬁ  cant changes were 
observed at 6 months in the papillary dermis in the tretinoin-
treated group, which supported the observation made in 
the initial short-term studies. However, after 12 months, 
formation of new collagen ﬁ  bers as well as reduction in 
nodularly degenerated microﬁ  brillar material was observed 
in the tretinoin-treated group. This study indicated that for 
appreciable dermal level improvement, more than 6 months 
of tretinoin therapy is required. This also provided an 
explanation why remarkable changes were observed only 
after 6 months of tretinoin treatment in the study carried 
out by Green and colleagues (1993). Olsen and colleagues 
Table 2 Overview of short-term studies on tretinoin
Reference  Study design  No. of patients  Duration  Observations in tretinoin group
Weiss et al (1988)  Randomized,  30  4 months  Compaction of stratum corneum
  Double-blind      Increase in glycosamine
  0.1% tretinoin cream       glycans (GAGs) 
  vs vehicle      Improvement in ﬁ  ne wrinkles,
        coarse wrinkles, tactile roughness,
       sallownessa
      
Lever et al (1990)  Double-blind  20  3 months  Epidermal thickening 
  0.05% tretinoin cream       Improvement in ﬁ  ne wrinklesa
  vs placebo control     
      
Shukuwa et al (1993)  Open-label  5  1 month  Compaction of stratum 
  0.05% tretinoin cream      corneum, Disappearance of atypia,
       dysplasia
       No  signiﬁ  cant dermal changes
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(1997a) evaluated the histological and clinical changes 
occurring in 298 patients after once daily application of either 
0.05% or 0.01% tretinoin emollient cream for a duration of 
1 year. Signiﬁ  cant improvement in histological and clinical 
markers was observed in both the 0.05% and the 0.01% 
tretinoin group as compared with vehicle. In another study, 
Oslen and colleagues (1997b) evaluated the 6 month effect of 
once weekly or thrice weekly 0.05% tretinoin emollient or no 
treatment in 126 individuals who had completed 48 months of 
0.05% once daily tretinoin therapy. Thrice weekly tretinoin 
treatment appeared to be more effective in improving the ﬁ  ne 
wrinkles than once weekly therapy whereas discontinuation 
of the therapy resulted in the reversal of beneﬁ  cial effects 
to some extent.
Bhawan and colleagues (1996) studied the effect of long-
term use (4 years) of tretinoin emollient cream in 27 patients 
treated with either 0.05% or 0.01% of tretinoin for the ﬁ  rst 
18 months, followed by 15-month treatment with 0.01% 
tretinoin and ﬁ  nally 19-month daily treatment with either 
0.025% or 0.05% tretinoin. Histological studies indicated 
that the stratum corneum became compact in the ﬁ  rst 3 to 
6 months whereas it returned to normal (basket weave 
pattern) in 12–24 months and remained normal until the 
end of the therapy. Likewise, granular layer thickness and 
epidermal thickness were increased in the ﬁ  rst 3–6 months, 
returned to normal in 12–24 months and remained normal 
until cessation of the therapy. In contrast, epidermal mucin 
continued to increase and melanin continued to decrease 
throughout tretinoin treatment. The changes in these 
2 components clearly correlated with the observed clinical 
changes.
Low-strength tretinoin
The concept of low strength tretinoin had gained interest 
when Grifﬁ  ths and colleagues (1995) reported observations 
made in a 48 week, double-blind, vehicle-controlled trial 
(n = 90) that compared clinical efﬁ  cacy and tolerability of 
0.025% and 0.1% tretinoin cream. The authors observed 
that both 0.025% and 0.1% tretinoin resulted in statistically 
signiﬁ  cant improvement in all histological and clinical 
signs of photoaging as compared with vehicle, but there 
were no clinically or statistically signiﬁ  cant differences 
Table 3 Overview of studies involving 6 months’ tretinoin treatment
Reference  Study design  Duration  No. of  Observations and Inferences
     patients
Leyden et al (1989)  Randomized, double-blind  6 months  30  Improvement in ﬁ  ne wrinkling, coarse wrinkling,
  0.05% tretinoin cream vs      sallowness and hyperpigmentation
 vehicle  control     
Caputo et al (1990)  Dose escalating study  6 months  89  Improvement in ﬁ  ne and coarse wrinkling, mottled
  tretinoin cream 0.01% in the       hyperpigmentation, skin texture and laxity
  1st month, 0.025% in the 2nd     
  month, 0.05% for next 4 months     
Weinstein et al (1991)  Double-blind  6 months  251  Signiﬁ  cant improvement in ﬁ  ne wrinkling, mottled
  tretinoin emollient cream      hyperpigmentation, roughness, laxity, epidermal 
  0.05% and 0.01% vs vehicle      thickness, in group treated with 0.05% tretinoin as
        compared with 0.01% and vehicle group
        Dose-dependant responses were observed
        No effect was seen in dermal thickness, collagen 
        regeneration, reversal of keratinocytic atypia
Bhawan et al (1991)  Randomized, Double-blind  6 months  533  Signiﬁ  cant improvement in ﬁ  ne wrinkling, mottled
  tretinoin emollient cream      hyperpigmentation, roughness, epidermal thickness, 
  0.001%, 0.01% and 0.05%      in group treated with 0.05% tretinoin as compared
  vs vehicle      with 0.01%, 0.001% and vehicle group
        Dose-dependant responses were observed
        Vehicle-treated group showed some improvement
Olsen et al (1992)  Same as in case of Bhawan et al  6 months  296  Same as in case of Bhawan et al (1991)
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between the two concentrations of tretinoin. However, the 
incidences of adverse effects were signiﬁ  cantly greater 
in the 0.1% tretinoin group as compared with the 0.025% 
tretinoin group. Thus, it was speculated that low strength 
tretinoin might be a good option for those patients who 
can not tolerate standard therapy (0.05%). Thereafter, 
Nykady and colleagues (2001) conducted two 24 weeks, 
double-blind and vehicle-controlled trials to evaluate the 
efﬁ  cacy and tolerability of 0.02% tretinoin cream applied 
once daily in 328 patients with moderate to severely 
photodamaged skin. Interestingly, both studies showed 
that there is signiﬁ  cantly greater improvement in clinical 
signs of photoaging like ﬁ  ne wrinkling, coarse wrinkling, 
sallowness, and mottled hyperpigmentation (only in one 
study) as compared with vehicle. Moreover, the treatment 
was safe and well tolerated in most of the patients. 
Tretinoin cream 0.02% is now recognized by the FDA for 
the treatment of photoaging.
High strength tretinoin
High strength tretinoin treatment has been evaluated in the 
treatment of photoaging as the conventional tretinoin therapy 
has following disadvantages:
1. Beneﬁ  cial effects of tretinoin are seen slowly and over a 
long period of time, which often leads to discontinuation 
of therapy.
2.  Retinoid related adverse effects like irritation, erythema 
and dermatitis.
Hence, in order to minimize or avoid these disadvantages, 
Kligman and colleagues (1998) evaluated the potential of 
high strength tretinoin (0.25% solution in a fast penetrating 
vehicle) for the treatment of photoaging in 50 females. 
The treatment regimen consisted of application of highly 
concentrated tretinoin solution on alternate nights for 
2 weeks and then every night thereafter until the end of 
the treatment. Interestingly, just 4 to 6 week treatment 
with high strength tretinoin resulted in improvement in 
fine wrinkling, mottled hyperpigmentation, elasticity, 
hydration, angiogenesis, and new collagen deposition above 
the zone of solar elastosis and the extent was similar to the 
results observed after 6 to 12 months of standard tretinoin 
therapy (0.05%). Moreover, the high strength tretinoin 
treatment was well tolerated in all patients. Subsequently, 
Cuce and colleagues (2001) evaluated efﬁ  cacy of the 
1% tretinoin solution applied twice a week in 15 women 
with photodamaged skin. Histological studies carried out 
after 15 days showed compaction of stratum corneum and 
increased epidermal thickness. Additionally, surface 
imaging studies showed improvement in skin texture and 
appearance. 
In another study, Kligman and colleagues (2004) 
investigated the effect of high strength solution applied every 
night in 32 women with photodamaged skin. Treatment for 
4 weeks resulted in signiﬁ  cant improvement in ﬁ  ne wrinkles, 
mottled hyperpigmentation, and roughness as observed in 
their earlier study. The most noteworthy, but unexpected 
observation in this study was the rapid accommodation of 
the skin to retinoid side effects occurring within just 2 weeks. 
Hence, although typical retinoid associated side-effects were 
observed, they diminished very soon resulting in tolerance 
and better acceptance of the therapy in the patients. Yet, 
although high strength tretinoin has shown a good potential 
in photoaging, the reported studies have been carried out in 
a smaller population. Hence, large scale, multicentric and 
standard tretinoin therapy (0.05%) controlled studies are 
required to conﬁ  rm the efﬁ  cacy.
Tretinoin in intrinsic aging
To date only one vehicle-controlled clinical study has been 
undertaken to evaluate the use of topical tretinoin for the 
treatment of chronologically aged skin. In this study, 0.025% 
tretinoin cream was applied once daily on chronologically 
aged inner thigh skin of six women (mean age, 74 years) for 
a period of 9 months (Kligman et al 1993). The cream was 
applied to one inner thigh and vehicle to the other. Clinically, 
the improvement with thigh skin was modest; showing a less 
scaly, a less wrinkled, and a little ﬁ  rmer skin with a pink hue. 
In contrast, histological changes associated with tretinoin 
treatment were much more marked, when compared with the 
vehicle. Tretinoin resulted in marked increase in epidermal 
and granular cell layer thickness and a highly undulating 
dermo-epidermal junction through the development of rete 
pegs and produced uniformity in keratinocyte density while 
it decreased melanocyte vacuolization. Ultrastructurally, 
an increase in anchoring ﬁ  brils was noted at the level of the 
dermo-epidermal junction. In the dermis, development of 
several new micro vasculatures (angiogenesis) and production 
of new elastic material and GAGs was observed. These 
morphological changes suggested that the magnitude of 
effect of tretinoin might be greater for chronologically aged 
than for photoaged skin. However, large scale, multicentric 
clinical trials need to be conducted for confirming the 
utility of tretinoin for chronological aging.Clinical Interventions in Aging 2006:1(4) 337
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Isotretinoin
The observed fact that topical isotretinoin (13-cis retinoic 
acid) results in a dose-dependent effacement of wrinkles 
with concomitant increase in the formation of normal 
connective tissues in UVB-irradiated hairless mice caught 
the interest of dermatologists in isotretinoin. Cunningham 
evaluated the potential of topical 0.1% isotretinoin cream 
in a randomized study of 6 months. Isotretinoin-treated 
patients showed statistically signiﬁ  cant improvement in 
the various symptoms of photoaging like ﬁ  ne wrinkles 
and pigmentation as compared with placebo-treated 
subjects (Cunningham 1990). Later, in 2 separate studies, 
the potential of isotretinoin in treating patients suffering 
from mild to moderate photodamage was evaluated by 
Sendagorta and colleagues (1992) (n = 776) and Armstrong 
and colleagues (1992) (n = 326) in double-blind, vehicle-
controlled clinical trials. In both studies, isotretinoin 
cream 0.05% was applied for 12 weeks, followed by 
application of higher strength isotretinoin (0.1% cream) 
during the next 24 weeks. Interestingly, both studies 
resulted in a statistically signiﬁ  cant improvement in 
overall appearance, ﬁ  ne wrinkling, discrete pigmentation, 
sallowness, and texture of photoaged skin without causing 
any signiﬁ  cant irritation (Armstrong et al 1992; Sendagorta 
et al 1992). 
Similarly, Maddin et al (2000) conducted a multicentric, 
double-blind and placebo-controlled trial of 0.1% 
isotretinoin cream in 800 patients with moderate-to-
severe photodamage. After 36 weeks of continuous daily 
treatment, the isotretinoin-treated group showed statistically 
signiﬁ  cant (p < 0.01) amelioration exceeding the one 
in the vehicle treated group in overall appearance, ﬁ  ne 
wrinkles, texture, coarse wrinkling, and hyperpigmented 
macules after 12 weeks of treatment which was evident 
up to 36 weeks. Moreover, histological studies indicated 
a significant increase in epidermal thickness of skins 
obtained from the isotretinoin-treated group. However, 
no signiﬁ  cant changes were observed in other histological 
parameters, such as dermal elastosis, thickness of the 
dermis, epidermal melanin content, number of ﬁ  broblasts, 
and melanocyte dysplasia or keratinocyte atypia. Although 
ﬁ  ve to ten percent patients experienced severe irritation, 
particularly on facial skin, most of the other patients 
experienced only mild irritation. Moreover, the plasma 
level of isotretinoin did not show sustained increase in 
its concentration over the period of 36 weeks indicating 
absence of drug accumulation. 
Topical isotretinoin has also been evaluated for the 
treatment of actinic keratoses. Alirezai and colleagues 
(1994) conducted a vehicle-controlled study which involved 
the use of 0.1% isotretinoin cream twice daily for 24 weeks. 
The study resulted in a statistically signiﬁ  cant reduction 
in actinic keratoses and precancerous facial lesions in the 
isotretinoin group, with 66% of 44 patients achieving a 
reduction in more than one-third of lesions. However, no 
signiﬁ  cant drug effect was seen for actinic keratoses on 
the scalp or upper extremities. Mild-to-moderate irritant 
reactions were observed in the isotretinoin treated group, 
but symptoms subsided with reduced frequency of the 
treatment.
Hernandez-Perez and colleagues (2000) conducted a 
study (n = 60) to evaluate clinical efﬁ  cacy of oral isotretinoin 
in the treatment of photoaging. The patients included 
in the study were divided into 2 groups, one of which 
received oral isotretinoin 10 mg to 20 mg thrice a week for 
2 months in addition to the facial rejuvenative treatment 
whereas the other group received only facial rejuvenative 
procedures. Interestingly, the isotretinoin-treated group 
showed statistically signiﬁ  cant improvement exceeding the 
other group in various parameters such as wrinkles, skin 
thickness, tone, elasticity, and mottled hyperpigmentation. 
However, studies in larger populations are needed to prove 
the beneﬁ  cial effects of oral isotretinoin therapy.
Griffiths and colleagues (2005) recently conducted 
a 6-month, multicentric, randomized, double-blind, 
parallel-group, vehicle-controlled study in 346 subjects with 
photoaged skin to evaluate the efﬁ  cacy of 0.05% isotretinoin 
in combination with sunscreens applied once daily. At the 
end of the study, patients receiving isotretinoin and sunscreen 
combination showed signiﬁ  cant improvement (p < 0.05) 
in ﬁ  ne wrinkles compared with the vehicle treated group. 
Moreover, the incidences of adverse effects were less in the 
isotretinoin-treated patients.
Retinol
Vitamin A alcohol or all-trans retinol belong to the family of 
endogenous natural retinoids and is a precursor for synthesis 
of endogenous retinal and retinoic acid. Although all-trans 
retinol has been used in OTC cosmetic products since 1984 
(Rolewski 2003), its potential in the treatment of photoaging 
was realized when Kang et al (1995) showed that application 
of all-trans-retinol on normal human skin induces epidermal 
thickening and enhances the expression of CRABP II and 
CRBP mRNAs and proteins, as does retinoic acid. Moreover, Clinical Interventions in Aging 2006:1(4) 338
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the authors also observed that retinol showed only minimal 
signs of erythema and irritation unlike tretinoin. In another 
study (n = 6; duration = 14 days), Fluhr and colleagues 
(1999) conﬁ  rmed that retinol produces considerably less 
transepidermal water loss, erythema and scaling than 
retinoic acid. Interestingly, Fisher and colleagues (1996, 
1997) further demonstrated that retinol inhibits UV 
induction of MMP and stimulates collagen synthesis in 
photoaged skin. However, it was observed that retinol is 
20 times less potent than tretinoin and it requires further 
conversion to retinoic acid (in vivo) to demonstrate its 
action (Kurlandsky et al 1994; Kang et al 1995). Duell and 
colleagues (1996) demonstrated that retinol could be as 
effective as retinoic acid in producing ‘retinoid mediated 
histological changes’ (like epidermal thickening and 
keratinocyte proliferation), but with much less irritancy. 
Pierard-Franchimont and colleagues (1998) ﬁ  rst conducted 
a controlled clinical trial with retinol formulation. They 
observed that retinol formulation resulted in signiﬁ  cant 
improvement in ﬁ  ne wrinkles after 12 weeks of treatment. 
Subsequently, Varani and colleagues (2000) studied the 
effect of topical application of 1% retinol in 53 individuals 
(80 years or above) with aged skin. The authors observed 
that retinol application for 7 days reduced MMP (matrix 
metalloproteinase), collagenase, and gelatinase expression 
with concomitant increase in ﬁ  broblast growth and collagen 
synthesis in the studied tissue specimens. Thus, it can be 
concluded that retinol should be effective in the treatment of 
aging and photoaging. However, the vehicle used for retinol 
delivery would play a crucial role in eliciting its efﬁ  cacy, 
as retinol is extremely unstable and easily gets degraded to 
biologically inactive forms on exposure to light and air.
Retinol derivatives
Retinol derivatives have been developed in order to improve 
the chemical stability of retinol. Retinol derivatives like 
retinyl acetate, retinyl propionate, and retinyl palmitate have 
been widely used in cosmetic products instead of retinol. 
In fact, retinol derivatives were thought to be useful for the 
treatment of photoaging after the observation that retinyl 
propionate induces epidermal thickening in mouse tail and 
promoted collagen formation in UV-irradiated mice (Green 
et al 1998). Based on these encouraging results, Green and 
colleagues (1998) conducted a double-blind, randomized 
and placebo-controlled trial for 48 weeks (n = 60). 
Unfortunately, topical retinyl propionate cream (0.15%) did 
not demonstrate any statistically signiﬁ  cant improvement 
over placebo in any of the evaluated histopathological or 
clinical symptoms of photoaging. However, in very few 
subjects, actinic keratoses were reduced virtually to zero 
by the end of 48 weeks, but this effect was not statistically 
signiﬁ  cant.
Han and colleagues (2003) have developed various 
retinol derivatives to improve the photostability of retinol 
while retaining its anti-aging activity. They found that N-
formyl aspartame derivative of retinol has a good potential 
(Figure 2) to act as anti-aging agent since it exhibited very 
good photostability. Moreover, it was very well tolerated by 
human ﬁ  broblasts and it suppressed collagenase expression 
(indication of anti-aging activity) as effectively as retinol. 
However, elaborate studies are still missing to demonstrate 
its in vivo efﬁ  cacy.
Retinol combinations
Combination therapies are gaining great importance in the 
treatment of cutaneous disorders like acne and psoriasis 
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as improved therapeutic effects have been observed 
with combination product compared with the respective 
monotherapy. Accordingly, researchers have recently 
attempted the use of retinol in combination with other anti-
aging agents.
Seité and colleagues (2005) conducted two double-
blind vehicle-controlled clinical studies in postmenopausal 
women to investigate the effects of a topically applied 
retinol plus vitamin C combination on epidermal and dermal 
compartments of aged or photoaged skin. 
Study 1 involved a 3-month treatment with a combination 
of retinol (0.07%) and vitamin C (3.5%) applied twice daily 
in 8 volunteers. After the 3-month treatment, histological 
changes such as thinning of stratum corneum, thickening 
of the viable epidermis, and increase in interdigitation 
index were observed. In the second study, volunteers with 
photoaged skin were treated for 6-months with retinol 
(0.04%) and vitamin C (3%) combination twice daily. After 
the 6-month topical treatment, the observed histological 
changes were mainly concentrated at the dermal level. Both 
treated and control groups showed the same distribution 
pattern of type I procollagen, however, the high level of 
type III procollagen originally observed in photoaged 
skin was reduced in the retinol- and vitamin C-treated 
group, resulting in a lower type III-to-type I procollagen 
ratio. Furthermore, a wide band of eosinophilic material 
just beneath the epidermis, devoid of oxytalan ﬁ  bers and 
forming the ‘grenz zone’, appeared more frequently and 
was larger in the retinol- and vitamin C treated group. 
Finally, the authors concluded that repeated topical 
application of a preparation containing both retinol and 
vitamin C could reverse, at least in part, skin changes induced 
by both chronological and photoaging.
Draelos (2005) recently conducted a controlled 
clinical trial to evaluate the efficacy of retinol (0.3%) 
and hydroquinone (4%) in the treatment of photoaging 
in comparison with 0.05% tretinoin emollient cream. 
Interestingly, the retinol – hydroquinone combination 
diminished the collective signs of photodamage more 
effectively than 0.05% tretinoin emollient cream in terms 
of dyspigmentation, ﬁ  ne wrinkles, and tactile roughness 
within 16 weeks of treatment. Feinberg and colleagues 
(2004) evaluated the efficacy of retinol (0.1%) and 
glycolic acid (8%) combination in comparison with the 
individual agents in the treatment of photoaging using the 
photodamaged arm methodology. They observed that retinol-
glycolic acid combination offered signiﬁ  cant improvement 
in the appearance of photoaged skin compared with glycolic 
acid or retinol alone. 
Barkovic and colleagues (2005) conducted a randomized, 
placebo-controlled, double-blind clinical trial in 
postmenopausal women to evaluate the efﬁ  cacy of retinol 
– dimethylenolamine combination in the treatment of 
chronological aging. The study demonstrated rapid and 
signiﬁ  cant improvements in the appearance of aging skin 
with daily application of the retinol – dimethylenolamine 
combination.
Retinaldehyde
Retinaldehyde is a retinoic acid precursor, which is formed 
as an intermediate metabolite in the transformation of 
retinol to retinoic acid in human keratinocytes. In the skin 
retinaldehyde is metabolized to retinoic acid (which is a 
well known anti-aging agent) as well as to retinol and retinyl 
esters (which generally get depleted during photoaging), 
indicating its use in the treatment of photoaging (Sass et al 
1996). Moreover, metabolism of retinaldehyde to retinoic 
acid occurs only by keratinocytes at a pertinent stage of 
differentiation, leading to a more controlled delivery of 
retinoic acid and weaker retinoid associated adverse effects 
as compared to tretinoin and other synthetic retinoids 
(Saurat et al 1994; Didierjean et al 1999; Sorg et al 1999). 
Saurat and colleagues (1994) ﬁ  rst evaluated the biological 
activity and tolerability proﬁ  le of retinaldehyde on human 
skin. Noteworthy, topical retinaldehyde was well tolerated 
on human skin and it also resulted in induction of CRABP 
type II mRNA and protein, increased epidermal thickness, 
increased keratin-14 expression, and enhanced keratinocyte 
proliferation. However, later it was shown that retinaldehyde 
exerts these biological activities only on transformation to 
retinoic acid (Didierjean et al 1999).
In an open clinical trial, Ochando and colleagues 
(1994) studied the effect of 0.05% retinaldehyde in 
32 female volunteers showing symptoms of mild to 
moderate photoaging. At the end of 4 months, considerable 
reduction in the surface roughness and coarse wrinkling 
was observed. Moreover, retinaldehyde treatment was 
associated with very few adverse effects. Subsequently, 
Creidi and colleagues (1998, 1999) conducted a randomized 
and vehicle-controlled clinical trial (n = 125) to compare 
the efﬁ  cacy of 0.05% retinaldehyde with 0.05% retinoic 
acid for the treatment of photoaging. Optical proﬁ  lometry 
studies on the volunteers indicated that both retinaldehyde 
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Mukherjee et al
and skin roughness. However, retinoic acid resulted in 
higher incidences of local irritation than retinaldehyde 
thus negatively affecting patient compliance. In another 
study, Diridollou and colleagues (1999) evaluated the 
effect of 0.05% retinaldehyde versus vehicle in 40 patients 
showing symptoms of aging by ultrasound and rheological 
techniques. Compared with the control group, the 
retinaldehyde treated group showed a signiﬁ  cant increase 
in epidermal thickness, as well as in cutaneous elasticity 
(p < 0.01). Similarly, retinaldehyde treatment tended to 
increase dermal thickness and reduce cutaneous stiffness 
and was very well tolerated by the patients. 
Recently, Mordon and colleagues (2004) conducted 
a monocentric, comparative, randomized, double-blind 
clinical trial (n = 16) to evaluate the efﬁ  cacy of retinaldehyde 
versus excipient both in combination with nonablative laser 
remodeling treatment. The study involved daily topical 
application of 0.05% retinaldehyde (8 patients) immediately 
after the ﬁ  rst laser treatment and up to 3 months after the 
ﬁ  fth treatment. The control group (8 patients) was treated 
under similar conditions, except with a daily application 
of vehicle instead of retinaldehyde.
At the end of the study, an increase in dermal thickness 
was observed for all patients treated by laser (both 
retinaldehyde and control groups) on the forehead and neck. 
However, the increase was greater for the retinaldehyde 
group (p < 0.05) when compared with the control group 
(vehicle). The increase in dermal thickness was 5.27% versus 
1.13% for the forehead and 10.54% versus 3.57% for the 
neck, respectively. 
Thus, it can be concluded that retinaldehyde is a useful 
topical agent for the treatment of aged and photoaged skin, 
with a lower frequency of irritation.
Tazarotene
Tazarotene is a novel acetylenic retinoid known to be 
effective in the topical treatment of psoriasis and acne. 
Tazarotene is a prodrug, rapidly metabolized to its active 
metabolite tazarotenic acid. Due to its rigid polyaromatic 
structure, it does not undergo any isomerization or 
conformational change in the skin. Although tazarotene 
belongs to the retinoid family, it displays a receptor 
selectivity pattern different from the one found with 
tretinoin. Tretinoin directly activates all RAR subtypes 
and indirectly RXRs whereas tazarotenic acid selectively 
binds to RAR-β and RAR-γ but not to RXRs. Tazarotenic 
acid modulates the expression of retinoid-responsive genes, 
including those that regulate cell proliferation, cell 
differentiation, and inflammation, corresponding to its 
binding capacities to various RAR receptors. Tazarotene also 
down-regulates the abnormal expression of keratinocytes, 
epidermal growth factor receptor, and hyperproliferative 
keratins (Nagpal et al 1995; Chandraratna 1996; DiSepio et al 
1998; Roeder et al 2004).
Sefton and colleagues (2000) ﬁ  rst conducted a pilot, 
double-blind, randomized trial to evaluate the efﬁ  cacy of 
0.1% tazarotene gel in 10 healthy women with moderate 
photodamage of the forearm skin. At the end of 12 weeks, 
signiﬁ  cant reduction in pigmentary mottling, ﬁ  ne wrinkling, 
and skin roughness were observed in the tazarotene 
treated group as evidenced in silicon skin surface replicas. 
Moreover, histopathological investigations indicated 
a reduction of keratinocytic atypia and a restoration of 
keratinocyte polarity. 
Tazarotene was further evaluated by Kang, Leyden, and 
colleagues (2001) who performed a multicentre, prospective, 
randomized study in 349 facially photodamaged subjects, 
to compare the efﬁ  cacy of four different concentrations 
of tazarotene (0.01%, 0.025%, 0.05%, and 0.1%) with its 
vehicle and with tretinoin 0.05% emollient cream. At the 
end of 24 weeks, treatment success rates based on global 
responses (>50% improvement compared with baseline) 
were signiﬁ  cantly higher in the tazarotene- and tretinoin-
treated groups than in the vehicle-treated group (67% 
with tazarotene 0.1%, 52% with tazarotene 0.05%, 36% 
with tazarotene 0.025%, 41% with tazarotene 0.01%, 55% 
with tretinoin 0.05% and 22% with vehicle). Interestingly, 
a significantly greater proportion of tazarotene-treated 
patients showed at least 50% improvement in various clinical 
parameters than tretinoin-treated patients at weeks 12 and 
20 thus indicating a trend towards a quicker response in 
tazarotene-treated patients. However, at the end of 24 weeks, 
there was no difference in overall improvement in the 
photodamage in tazarotene- or tretinoin-treated groups. In 
this study, both tazarotene 0.1% and tretinoin 0.05% cream 
showed a similar degree of improvement in epidermal 
thickness, ﬁ  ne wrinkling, lentigines, elastosis, and mottled 
hyperpigmentation. The local adverse events observed were 
generally of mild or moderate severity, and were greater 
(mainly burning) with higher tazarotene concentrations. 
Recently, Lowe and colleagues (2004) again compared 
the efficacy of tazarotene 0.1% cream and tretinoin 
0.05% emollient cream in the treatment of photoaging in 
a double-blind, randomized, multicentre, 24 week study Clinical Interventions in Aging 2006:1(4) 341
Retinoids in the treatment of skin aging
(n = 173). At week 16, the incidence of treatment success 
(>50% global improvement) at the study endpoint was 78% 
in the tazarotene group and 67% in the tretinoin emollient 
group, with statistical signiﬁ  cance in favor of tazarotene. All 
other signiﬁ  cant differences in efﬁ  cacy measures were also 
in favor of tazarotene – for the overall integrated assessment 
of photodamage at week 16, ﬁ  ne wrinkling at week 24, 
mottled hyperpigmentation at weeks 12 and 16, and coarse 
wrinkling at week 4. There were no signiﬁ  cant between-
group differences in the incidence of subjects achieving at 
least a 1-grade improvement in irregular depigmentation, 
lentigines, appearance of pore size, elastosis, tactile 
roughness, telangiectasia, and actinic keratoses. The local 
adverse events observed were generally of mild or moderate 
severity and were greater (mainly burning) with higher 
tazarotene concentrations. Thus, the efﬁ  cacy and tolerability 
results obtained from this study are in broad agreement with 
those reported by Kang, Leyden, and colleagues (2001).
Phillips and colleagues (2002) conducted a multicentre, 
double-blind, randomized, vehicle-controlled clinical 
trial that involved treatment of 563 subjects with 
facial photodamage with tazarotene 0.1% cream for 
24-weeks followed by a 28-week open-label extension. At 
week 24, when compared with vehicle, tazarotene resulted 
in a signiﬁ  cantly greater proportion of patients achieving 
treatment success (>50% greater improvement) and at 
least a 1 grade improvement in ﬁ  ne wrinkling, mottled 
pigmentation, pore size, lentigines, elastosis, irregular 
depigmentation, tactile roughness, coarse wrinkling, and 
overall integrated assessment of photodamage. Pigmentary 
changes were the ﬁ  rst to respond to treatment, showing 
statistically signiﬁ  cant improvement over vehicle after 
2 weeks of treatment. Fine wrinkling improved in the 
tazarotene group after 4 weeks of treatment, and coarse 
wrinkles, elastosis, and pore size were significantly 
improved over vehicle by week 12. Telangiectasia and 
actinic keratoses were not signiﬁ  cantly improved after 
24 weeks of treatment, these two variables not being the 
primary outcome measures of the study. After the ﬁ  rst 
24 weeks, an open label extension of tazarotene 0.1% 
cream was followed for another 28 weeks. Additional 
clinical improvement was noted, which did not plateau 
after 52 weeks of treatment, suggesting the value of long-
term treatment. Irritation was generally mild or moderate 
and declined with ongoing treatment, whereas plasma 
tazarotenic acid concentration did not exceed the plasma 
levels of endogenous retinoids.
Recently, tazarotene has been evaluated once again 
against photodamage in two subsequent studies. Machtinger 
and colleagues (2004) evaluated the histological effects of 
tazarotene cream in 50 patients with photodamaged facial 
skin by conducting a multicentre, double-blind, randomized, 
vehicle-controlled study. Blinded assessments showed 
that the tazarotene-treated group showed amelioration 
of keratinocytic and melanocytic atypia compared to the 
vehicle-treated group. Between-group comparisons in 
distribution of change from baseline categories of severity 
were in favour of tazarotene (p = 0.055 for keratinocytic 
atypia, p = 0.034 for melanocytic atypia, and p < 0.001 for 
the number of granular cell layers). Compared with vehicle, 
tazarotene was associated with an increase in epidermal 
polarity (p = 0.008) and epidermal thickness (p = 0.012), and 
a tendency for stratum corneum compaction. Tazarotene was 
also associated with widened intercellular spaces relative to 
vehicle (p < 0.001).
In another study, Kang and colleagues (2005) evaluated 
the efﬁ  cacy and tolerability of tazarotene 0.1% cream in the 
treatment of 568 patients with facial photodamage. Topical 
tazarotene offered efﬁ  cacy in ameliorating multiple effects 
of photodamage. Tazarotene cream was signiﬁ  cantly more 
effective than vehicle in reducing ﬁ  ne wrinkles, mottled 
hyperpigmentation, lentigines, irregular depigmentation, 
apparent pore size, elastosis, tactile roughness, and an overall 
integrated assessment of photodamage. Signiﬁ  cance was 
achieved as early as at week 2 with mottled hyperpigmentation, 
lentigines, irregular depigmentation and elastosis and had 
not plateaued by week 24. The majority of patients reported 
improvements in their photodamage as early as at week 4. 
Adverse events were predominantly mild or moderate signs 
or symptoms of skin irritation. Thus, topical tazarotene has 
been shown to offer efﬁ  cacy in ameliorating multiple effects 
of photodamage.
Adapalene
Adapalene is considered to be a third-generation synthetic 
retinoid which contains a napthoic acid backbone. Unlike 
retinoic acid, adapalene shows selectivity for the nuclear 
retinoic acid receptor (RAR β/γ). It targets abnormal 
desquamation of the skin, modulates cellular differentiation, 
and possesses anti-inﬂ  ammatory properties (Leyden 2001). 
Moreover, due to its receptor selectivity, it causes less skin 
irritation. Adapalene is successfully being used for the 
treatment of acne. However, not much has been done to 
investigate its potential in aging/photoaging. So far only Clinical Interventions in Aging 2006:1(4) 342
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one study has been carried out to determine the potential of 
adapalene in photoaging. 
Kang and colleagues (2003) conducted a 2-center, 
randomized, vehicle-controlled, investigator-masked, 
parallel-group study in 83 patients suffering from actinic 
keratoses and solar lentigines and other symptoms of 
photoaging to evaluate the therapeutic potential of 
adapalene gel (0.1% or 0.3%) or vehicle for 4 weeks, 
followed by twice-daily applications, if tolerated, for up 
to 9 months. After 9 months, 0.5 + 0.9% and 2.5 + 0.9%, 
reduction in actinic keratoses was observed with adapalene 
gel 0.1% and 0.3%, respectively. Whereas, with the vehicle 
gel actinic keratoses increased by 1.5 + 1.3% (p < 0.005).
Signiﬁ  cant lightening of solar lentigines was observed 
in patients treated with adapalene gel as compared with the 
patients treated with vehicle gel (p < 0.05) within 1 month 
of treatment. At the end of 9 months, 57% and 59% of the 
patients had brighter lesions in the adapalene 0.1% and 
0.3% groups, respectively, in comparison with only 36% 
in the vehicle group (p < 0.05). Moreover, histological 
evaluations revealed improved cellular atypia and reduced 
epidermal melanin content in the adapalene-treated group 
compared with the vehicle-treated group. A retrospective 
evaluation of paired clinical photographs (before and after 
9-month treatment) revealed signiﬁ  cant improvement in 
wrinkles and other clinical features of photoaged skin 
with adapalene as compared with its vehicle. As expected, 
adapalene was very well tolerated by the patients involved 
in the study. Thus, adapalene can be employed as a second 
line treatment of photoaging mainly in patients demonstrating 
extreme intolerance to conventional retinoids. However, 
large scale clinical trials should be carried out to validate 
the efﬁ  cacy of adapalene.
Alitretinoin
Alitretinoin or 9-cis-retinoic acid is a naturally occurring 
endogenous retinoid that binds to and activates all known 
intracellular RAR and RXR subtypes (Cheer and Foster 
2000). Its use in the topical treatment of AIDS-associated 
Kaposi’s sarcoma is well documented in the literature 
(Bodsworth et al 2001). Additionally, its safety and efﬁ  cacy 
in the normal treatment of chronic hand dermatitis has also 
been proved (Ruzicka et al 2004). Considering the RAR 
binding activity of alitretinoin, Baumann and colleagues 
(2005) recently conducted an open-label pilot study in 20 
patients with photodamaged skin to evaluate the efﬁ  cacy 
of 0.1% topical alitretinoin. The topical alitretinoin 
treatment showed improvement in seborrheic keratoses, 
actinic keratoses, and other symptoms of photoaging. 
Moreover, the treatment was well tolerated by the patients. 
However, larger, blinded, controlled trials are needed to 
know the role and efﬁ  cacy of alitretinoin in the treatment 
of photoaging.
Seletinoid G
Seletinoid G represents a fourth generation of retinoids that 
might ﬁ  nd an important place in the treatment of intrinsic/
photo aging. Like other synthetic retinoids, seletinoid G shows 
receptor selectivity for RAR-γ, which is predominantly 
expressed in the epidermis as compared with other RARs. 
Recently, Kim and colleagues (2005) evaluated the safety 
and efﬁ  cacy of seletinoid G in comparison with tretinoin 
for the treatment of intrinsic/photo-aging after topical 
application in 23 patients belonging to differing age groups. 
Notably, intrinsically aged skin after topical treatment 
with seletinoid G showed increase in the expressions 
of type I procollagen, tropoelastin, and ﬁ  brillin-1, and 
reduced MMP-1 similar to that of tretinoin demonstrating 
its potential in the treatment of intrinsic aging. Moreover, in 
the UV-irradiated young skin, topical seletinoid G treatment 
inhibited UV-induced decrease of type I procollagen and 
UV-induced increase of MMP-1 and c-Jun protein similar 
to that seen with tretinoin. Interestingly, topical application 
of seletinoid G under occlusion induced no skin irritation 
in contrast to tretinoin, which caused severe erythema. 
Thus, seletinoid G appears to be as effective as tretinoin 
in the treatment of intrinsic/photo aging with the added 
advantage of absence of skin irritation. However, larger, 
blinded, controlled trials are needed to validate the role 
and beneﬁ  t-to-risk ration of seletinoid G in the treatment 
of intrinsic/photo aging.
Adverse effects of topical retinoids
The most common and frequent adverse effect of topical 
retinoids are known as ‘retinoid reaction’, characterized 
by pruritus, burning sensation at the sites of application, 
erythema, peeling. It is more common with tretinoin and 
tazarotene than with isotretinoin, adapalene, retinol, and 
retinaldehyde. The ‘retinoid reaction’ has been found to 
be due to the free carboxylic acid in the polar end of the 
retinoid, which is evident from the activity and toxicity 
experiments done on CHO cells (Oda et al 1996). ‘Retinoid 
reaction’ manifests itself generally within the ﬁ  rst few weeks 
of treatment and is thought to get initiated by release of Clinical Interventions in Aging 2006:1(4) 343
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proinﬂ  ammatory cytokines such as IL-1, TNF-α, IL-6, and 
IL-8 (Torras 1996; Orfanos et al 1997). In order to validate 
this hypothesis, Kim and colleagues (2003) evaluated the 
changes in mRNA expression of inflammation-related 
cytokines such as human monocyte chemoattractant 
protein-1 (MCP-1), IL-8, TNF-α, interferon-γ (IFN-γ), IL-6, 
IL-10, after treatment of epidermal cells with retinoic acid 
and retinol. A minimum 3-fold increase in the mRNA and 
protein levels of mainly MCP-1 and IL-8 were found, thus 
validating the hypothesis to some extent.
The other side effect associated with retinoid therapy is 
photosensitization, which normally occurs at the beginning of 
the therapy. Patients on retinoid therapy are advised to avoid 
excessive sun exposure and take precautionary measures 
(like use of sunscreens) for sun protection. However, after 
few months of therapy, the skin’s response to UV radiation 
returns to normal. In certain cases, irritant conjunctivitis has 
also been reported when the retinoid is applied close to the 
eye (Torras 1996).
Over the past 30 years, no systemic side-effects on long-
term treatment with the topical retinoid have been observed 
in young adults. Moreover, Lattarino and colleagues (1997) 
found that topical tretinoin had no detectable effect on 
endogenous plasma levels of tretinoin or its metabolites. 
This is mainly because of the limited transdermal uptake 
of these agents (Krautheim and Gollnick 2003). Pregnant 
women or women of child-bearing age should use topical 
retinoids with caution as retinoids on systemic exposure 
are known to cause teratogenicity/embryotoxicity. 
However, in over 25 years of topical tretinoin use for acne 
therapy there have been no cases of related teratogenicity 
(Kligman 1988). Additionally, in one case-control study of 
215 mothers who were exposed to topical tretinoin in the 
ﬁ  rst trimester of pregnancy, the prevalence of major fetal 
malformations in the tretinoin-exposed group was 1.9% 
versus 2.6% in the control group, indicating the safety of 
topical tretinoin (Jick et al 1993). Even then, it is prudent 
to advise women of childbearing age to avoid pregnancy 
during treatment or, if pregnant, to discontinue the use of 
topical retinoids.
Counteracting the adverse effects
To counteract the symptoms of retinoid reaction, reduction 
in the frequency of application or switching to a less 
irritating retinoid is normally advised. Moreover, addition 
of 3% indomethacin or 1% hydrocortisone to the retinoid 
formulation, or concomitant treatment with a low to medium 
potency topical corticosteroid has also been suggested to 
relieve the symptoms (Torras 1996). However, if patients 
cannot tolerate even the lowest concentration of retinoids, 
then the treatment should be discontinued.
Kim and colleagues (2003) have demonstrated that 
concomitant application of natural agents or extracts 
like β-sitosterol, Magnoliae ﬂ  os, β-glycyrrhetinic acid, 
Scleroglucan, Gingko extract, Raspberry extract, Schisandra 
extract, Cola extract, Enna complex, or Vegetol red 
grapevine extract could also be useful in counteracting 
the irritant effects produced by topical retinoids. The 
abovementioned natural agents or extracts reduced the 
secretion of MCP-1 and IL-8 from human ﬁ  broblasts and 
also showed a good protection against the retinoid-induced 
irritation in the rabbit and human patch test. A different 
approach to reduce adverse events of retinoids was applied 
by Kambayashi et al (2005). Topical application of a new 
synthetic retinoid (N-retinoyl-D-glucosamine) to hairless 
mice showed good efﬁ  cacy in repair of photoaged skin 
but did not induce skin irritations compared with retinoic 
acid.
Although the aforementioned approaches have shown 
potential in minimizing the side effects, they involve co-
administration of other therapeutic agents, which may 
have its own effects on prolonged duration. The need of 
hour is to have an approach that can efﬁ  ciently counteract 
the adverse effects associated with retinoid therapy and 
would not require co-administration of any therapeutic 
agent. In fact, we believe that the same could be achieved 
by modulating the delivery system/s employed for topical 
retinoids. The further part of the review describes the 
potential of delivery systems in optimizing topical retinoids 
therapy with concomitant minimization in the adverse effects 
associated with it. 
Potential of delivery systems 
in topical retinoids therapy
Drug delivery strategies are well known in pharmaceutical 
research for their potential in optimizing efficacy 
of therapeutic agents by either modulating their 
physicochemical and biopharmaceutical properties or 
minimizing/eliminating the side effects associated with 
them, thus offering better patient compliance. The arrival 
of controlled release systems, transdermal delivery systems, 
implants, submicronic emulsions, and vesicular carriers 
is sufﬁ  cient to substantiate the aforementioned advantage 
of delivery systems. Since the last decade, there has been Clinical Interventions in Aging 2006:1(4) 344
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considerable interest in investigating the approaches for 
improved delivery of retinoids.
The delivery system can be considered to be efﬁ  cient for 
topical retinoids if it can:
1.  Minimize/abolish the adverse effects of topical 
retinoids.
2.  Improve the stability (mainly photochemical) of retinoids 
like retinoic acid and retinol.
3.  Enhance the anti-aging effect of retinoids by modulating 
their dermal transport or distribution.
Considering the above points, we believe that nanoparticles 
can be utilized as an efﬁ  cient delivery system to optimize 
the topical retinoid therapy. 
Nanoparticles are solid colloidal particles, ranging in size 
from 1 nm to 1000 nm, consisting of various biocompatible 
matrices in which a therapeutic moiety can be adsorbed, 
entrapped, or covalently attached (Lockman et al 2002). 
Based on the nanoparticles matrix (or shell), they are be 
classiﬁ  ed as: 
1. Polymeric  nanoparticles,
2.  Solid lipid nanoparticles,
3. Inorganic  nanoparticles.
Nanoparticles are extensively being investigated for drug 
delivery in the pharmaceutical research from the last 3 
decades on. Nanoparticles offer immense beneﬁ  ts such 
as solubilization of hydrophobic actives, improvement in 
bioavailability, improved (or altered) pharmacokinetics of 
active pharmaceutical ingredient (API), protection of API 
from physical, chemical or biological degradation, improved 
cellular uptake, tissue targeting and controlled release of API. 
However, most of the initial investigations on nanoparticles 
dealt with the parenteral or oral delivery of APIs whereas 
efforts to explore the potential of nanoparticles in topical 
delivery were initiated in the last decade. Interestingly, 
nanoparticles were found to improve the distribution 
characteristics and stability of topically applied APIs such 
as sunscreens (Wissing and Muller 2002). 
In addition, they have been shown to offer localized and 
targeted delivery of APIs which can be helpful in improving 
their efﬁ  cacy with concomitant reduction in systemic side 
effects associated.
Jenning and colleagues (Jenning, Gylser, et al 2000; 
Jenning, Schäfer-Korting, et al 2000; Jenning and Gohla 
2001) ﬁ  rst evaluated the potential of solid lipid nanoparticles 
(SLNs) for the delivery of retinol. Interestingly, SLNs 
offered a signiﬁ  cant improvement in the stability of retinol as 
compared with the conventional emulsion. Moreover, highly 
localized and controlled release of retinol could be observed 
with the SLNs. Patravale and colleagues (2004) investigated 
the potential of SLNs in counteracting the irritant effects and 
in improving the physical stability of the most commonly 
employed retinoid, ie, tretinoin. In fact, SLN-based tretinoin 
gels showed drastic improvement in the tolerability of 
tretinoin as compared with marketed products when 
evaluated by the Draize patch test in rabbits. Furthermore, 
photostability of tretinoin was markedly improved in SLNs 
as compared with methanolic solution. Again as expected, 
the tretinoin SLNs showed a high degree of localization in 
skin when evaluated by in vitro skin permeation studies. All 
these effects were attributed to the encapsulation of tretinoin 
in nanoparticulate structures.
Recently, Yamaguchi and colleagues (2005) have 
investigated the potential of inorganic nanoparticles of 
tretinoin produced by boundary-organized reaction. As 
observed earlier, tretinoin encapsulation in nanoparticles 
resulted in significantly less irritation and inflammation 
as compared with conventional formulation. In addition, 
nanoparticulate tretinoin showed drastic improvement in 
photostability as compared with conventional formulation, 
which was retained even after 46 days of storage. However, the 
most striking results were observed in the ex-vivo studies. 
Histological evaluation in mouse epidermis after daily 
application of nanoparticulate tretinoin cream for 4 days 
revealed more than double increase in epidermal thickness 
than conventional tretinoin vaseline preparation. Additionally, 
nanoparticulate tretinoin treatment resulted in a signiﬁ  cant 
increase in the mRNA levels of heparin-binding epidermal 
growth factor. This observation was in good correlation 
with the increased epidermal thickening observed with 
nanoparticulate tretinoin. Interestingly, 4 days’ treatment 
of aged skin of hairless mice with nanoparticulate tretinoin 
showed signiﬁ  cant improvement in ﬁ  ne and coarse wrinkling 
and texture in the neck area. To our knowledge, this is the ﬁ  rst 
investigation, which clearly demonstrated that nanoparticles 
could be an ideal approach in optimizing the topical retinoid 
therapy with concomitant reduction in the side effects 
associated with this therapy. 
Other delivery strategies 
for retinoids
Literature indicates that apart from nanoparticles, various 
other formulation approaches like liposomes, microsponges, 
microemulsions, and inclusion complexes with cyclodextrins 
could also be employed for improving the topical delivery Clinical Interventions in Aging 2006:1(4) 345
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of retinoids. Their success in improving the stability, 
tolerability, and efﬁ  cacy (in acne treatment) of retinoids is 
well established. However, none of them have been evaluated 
for improving the efﬁ  cacy of retinoids in the treatment of 
aging. The detailed description of their potential in improving 
the efﬁ  cacy and tolerability in the treatment of acne has been 
described by Date and colleagues (2006).
Conclusion and outlook
Aging research is divided into 2 main streams the one being 
the exploration of various pathophysiological and molecular 
events responsible for aging and the other being investigation 
on various anti-aging agents. Although much elaborate 
mechanistic studies have been carried out for understanding 
the pathophysiology of aging, they will still continue until 
the complete cascade of molecular events responsible for 
intrinsic/photoaging is elucidated. Amongst various anti-
aging agents, retinoids are the most promising agents that 
are available for the treatment of aging. Amongst retinoids, 
tretinoin is the most potent and best-studied retinoid. 
However, its irritation potential has prompted dermatologists 
to switch over to less irritating but comparably effective 
retinoids like adapalene and to some extent retinol and 
retinaldehyde. Receptor speciﬁ  c retinoids like seletinoid G 
have been developed with the same vision and have been 
found to be successful in small-scale studies.
We believe that future efforts in retinoid research will be 
directed in following ways
1.  Development of receptor selective synthetic retinoids 
(like seletinoid G) or novel retinoid derivatives (like 
N-formyl aspartamate derivative of retinol) or retinoid 
co-drugs like retinyl ascorbate (Abdulmajed and Heard 
2004) which may be superior in terms of tolerability, 
stability and efﬁ  cacy.
2.  Exploration of natural sources to identify agents or 
extracts that may have retinoid like activity as in case of 
PADMA 28 (Aslam et al 2005). 
3.  Evaluation of various combinations of anti-aging agents 
having synergistic effects (analogous to combination 
therapy in acne and psoriasis).
4.  Development and clinical evaluation of nanoparticulate 
carriers for retinoids.
Considering the developmental cost and the success rates 
associated with the new chemical entities, there is limited 
potential for developing novel synthetic retinoids. At the 
same time, retinoid-like activity as shown by PADMA 28 
opens a new era in the identification of natural products for 
anti-aging treatment. As natural products have the well 
known benefit of good acceptability we expect stimulation 
in this area of research. Combination therapy has been 
well established for cutaneous disorders like acne and 
psoriasis. As relatively less developmental efforts are 
required for commercializing new combinations, there is 
scope for developing retinoid based combination therapies 
for improved treatment of aging. Finally, in our opinion, 
there is great scope for development of various drug 
delivery systems (especially nanoparticulate systems) 
to optimize the aging treatment with topical retinoids. 
We believe that among various nanoparticulate carriers, 
SLNs would have the greatest potential in optimizing 
the retinoid therapy as apart from their advantage as a 
carrier they are also known to have a UV-blocking effect, 
which may help in reducing photosensitization induced 
by retinoids. Interestingly, in one study, a SLN-based 
anti-aging product was more effective in reducing the 
depth of wrinkles (10.3%) as compared with the same 
product based on conventional vehicle (4.1%) indicating 
that SLNs themselves may have some effect on improving 
wrinkling (Muller et al 2002). We believe that future 
efforts in SLNs should be focused on proving its potential 
to counteract photosensitivity and to identify the potential 
of SLNs (blank or in combination with retinoids) in 
improving the elasticity and wrinkling of intrinsically/
photo aged skin. Finally, complementary efforts from 
clinicians are required to validate the potential of drug 
delivery strategies in optimizing treatment of aging with 
topical retinoids.
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